ES2929200T3 - Tienopirroles sustituidos como inhibidores de PAD4 - Google Patents
Tienopirroles sustituidos como inhibidores de PAD4 Download PDFInfo
- Publication number
- ES2929200T3 ES2929200T3 ES19759134T ES19759134T ES2929200T3 ES 2929200 T3 ES2929200 T3 ES 2929200T3 ES 19759134 T ES19759134 T ES 19759134T ES 19759134 T ES19759134 T ES 19759134T ES 2929200 T3 ES2929200 T3 ES 2929200T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- alkyl
- independently selected
- occurrence
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862715834P | 2018-08-08 | 2018-08-08 | |
| PCT/US2019/045426 WO2020033490A1 (en) | 2018-08-08 | 2019-08-07 | Substituted thienopyrroles as pad4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2929200T3 true ES2929200T3 (es) | 2022-11-25 |
Family
ID=67766300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19759134T Active ES2929200T3 (es) | 2018-08-08 | 2019-08-07 | Tienopirroles sustituidos como inhibidores de PAD4 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11981680B2 (https=) |
| EP (1) | EP3833671B1 (https=) |
| JP (1) | JP7447080B2 (https=) |
| KR (1) | KR102851932B1 (https=) |
| CN (1) | CN112566916B (https=) |
| ES (1) | ES2929200T3 (https=) |
| WO (1) | WO2020033490A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001565A (es) | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
| JP7447080B2 (ja) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐａｄ４阻害剤としての置換チエノピロール |
| TW202115083A (zh) * | 2019-09-27 | 2021-04-16 | 大陸商南京藥捷安康生物科技有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
| WO2021158840A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Macrocyclic pad4 inhibitors useful as immunosuppressant |
| TW202140477A (zh) | 2020-02-12 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 雜環ｐａｄ４抑制劑 |
| WO2021222353A1 (en) | 2020-04-30 | 2021-11-04 | Gilead Sciences, Inc. | Macrocyclic inhibitors of peptidylarginine deiminases |
| EP4178963A1 (en) * | 2020-07-02 | 2023-05-17 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| CN116940578A (zh) * | 2020-07-02 | 2023-10-24 | 雷密克斯医疗公司 | 5-[5-(哌啶-4-基)噻吩并[3,2-c]吡唑-2-基]吲唑衍生物和相关化合物作为调节剂用于剪接核酸和治疗增殖性疾病 |
| TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
| WO2022140390A1 (en) | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
| US20250109140A1 (en) * | 2022-01-05 | 2025-04-03 | Remix Theraputics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| AU2023387505B2 (en) * | 2022-11-24 | 2026-03-05 | Helios Huaming Biopharma Co., Ltd. | Selenium containing heterocycle compounds and use thereof |
| KR20260041867A (ko) | 2023-07-21 | 2026-03-27 | 브리스톨-마이어스 스큅 컴퍼니 | Pad4 조정제의 시트룰린화 및 활성을 평가하는 방법 |
| WO2026020127A2 (en) | 2024-07-19 | 2026-01-22 | Bristol-Myers Squibb Company | Methods of assessing citrullination and activity of pad2 modulators |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101916443B1 (ko) | 2012-07-26 | 2018-11-08 | 글락소 그룹 리미티드 | Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸 |
| KR20180005250A (ko) | 2015-05-21 | 2018-01-15 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Pad4 억제제로서의 벤조이미다졸 유도체 |
| AR107030A1 (es) | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
| AR107032A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores bicíclicos de pad4 |
| US10654814B2 (en) | 2015-12-22 | 2020-05-19 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
| CA3015482A1 (en) * | 2016-02-23 | 2017-08-31 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of pad4 |
| WO2018022897A1 (en) | 2016-07-27 | 2018-02-01 | Padlock Therapeutics, Inc. | Covalent inhibitors of pad4 |
| US11026937B2 (en) | 2016-09-12 | 2021-06-08 | Padlock Therapeutics, Inc. | Heteroaryl inhibitors of PAD4 |
| JP7311228B2 (ja) | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用 |
| AU2018352142B2 (en) | 2017-10-18 | 2022-08-25 | Jubilant Epipad LLC | Imidazo-pyridine compounds as PAD inhibitors |
| TWI762769B (zh) * | 2018-02-26 | 2022-05-01 | 大陸商藥捷安康(南京)科技股份有限公司 | 肽醯精胺酸脫亞胺酶抑制劑及其用途 |
| MX2021001471A (es) * | 2018-08-08 | 2021-04-28 | Bristol Myers Squibb Co | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |
| MX2021001565A (es) | 2018-08-08 | 2021-04-19 | Bristol Myers Squibb Co | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). |
| JP7447080B2 (ja) | 2018-08-08 | 2024-03-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐａｄ４阻害剤としての置換チエノピロール |
| US20220348562A1 (en) | 2018-08-08 | 2022-11-03 | Bristol-Myers Squibb Company | Benzimidazole inhibitors of pad enzymes |
-
2019
- 2019-08-07 JP JP2021506663A patent/JP7447080B2/ja active Active
- 2019-08-07 WO PCT/US2019/045426 patent/WO2020033490A1/en not_active Ceased
- 2019-08-07 CN CN201980053221.6A patent/CN112566916B/zh active Active
- 2019-08-07 ES ES19759134T patent/ES2929200T3/es active Active
- 2019-08-07 US US17/265,833 patent/US11981680B2/en active Active
- 2019-08-07 EP EP19759134.0A patent/EP3833671B1/en active Active
- 2019-08-07 KR KR1020217006481A patent/KR102851932B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11981680B2 (en) | 2024-05-14 |
| US20220064180A1 (en) | 2022-03-03 |
| CN112566916B (zh) | 2023-10-20 |
| JP2021534106A (ja) | 2021-12-09 |
| EP3833671A1 (en) | 2021-06-16 |
| WO2020033490A1 (en) | 2020-02-13 |
| KR102851932B1 (ko) | 2025-08-27 |
| KR20210042935A (ko) | 2021-04-20 |
| EP3833671B1 (en) | 2022-08-24 |
| JP7447080B2 (ja) | 2024-03-11 |
| CN112566916A (zh) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2929200T3 (es) | Tienopirroles sustituidos como inhibidores de PAD4 | |
| ES2956090T3 (es) | Inhibidores de bencimidazol de enzimas PAD | |
| ES2973714T3 (es) | Bencimidazoles sustituidos como inhibidores de PAD4 | |
| ES2977683T3 (es) | Derivados de bencimidazolona y análogos de los mismos, como moduladores de IL-17 | |
| CN112805067B (zh) | Pad酶的吲哚及氮杂吲哚抑制剂 | |
| ES2828623T3 (es) | Inhibidores covalentes de PAD4 | |
| ES2924522T3 (es) | Inhibidores heteroarilo de PAD4 | |
| JP7711073B2 (ja) | 免疫抑制剤として有用な大環状ｐａｄ４阻害剤 | |
| EP3710431A1 (en) | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same | |
| KR20160073413A (ko) | 퀴나졸리논 및 이소퀴놀리논 유도체 | |
| ES2895904T3 (es) | Tetrahidroindazoles y usos médicos de los mismos | |
| CN118679150A (zh) | Cdk2抑制剂及其制备方法和用途 | |
| ES2374449T3 (es) | Compuestos de imidazol sustituidos como inhibidores de ksp. | |
| WO2026075941A1 (en) | Pyridazinone derivatives as pad4 inhibitors | |
| KR20080002935A (ko) | 피라졸로［1,5-ａ］피리딘 유도체 또는 그 의학상 허용되는염 |